Targeting of heat-shock protein 32/heme oxygenase-1 in canine mastocytoma cells is associated with reduced growth and induction of apoptosis

Experimental Hematology

Volumn 36, Issue 11, 2008, Pages 1461-1470

  Hadzijusufovic, Emir ^a,b   Rebuzzi, Laura ^a,b   Gleixner, Karoline V ^b   Ferenc, Veronika ^b   Peter, Barbara ^a,b   Kondo, Rudin ^b   Gruze, Alexander ^d   Kneidinger, Michael ^b   Krauth, Maria Theresa ^b   Mayerhofer, Matthias ^c   Samorapoompichit, Puchit ^e   Greish, Khaled ^f   Iyer, Arun K ^f   Pickl, Winfried F ^d   Maeda, Hiroshi ^f   Willmann, Michael ^a   Valent, Peter ^b  

^a UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^b Department of Internal Medicine I

^c Clinical Institute of Medical

^d Institute of Immunology

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f SOJO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; HEAT SHOCK PROTEIN 32; HEME OXYGENASE 1; HEMIN; MESSENGER RNA; MIDOSTAURIN; PROTOPORPHYRIN ZINC; RAPAMYCIN; STEM CELL FACTOR;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG POTENTIATION; EXPERIMENTAL DOG; GENE OVEREXPRESSION; IC 50; IMMUNOCYTOCHEMISTRY; MASTOCYTOMA; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

CANIS FAMILIARIS;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DOGS; HEME OXYGENASE-1; MASTOCYTOMA; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-KIT; RNA, MESSENGER;

EID: 53749098423     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2008.06.002     Document Type: Article

References (48)

1. Lennert K., and Parwaresch M.R. Mast cells and mast cell neoplasia: a review. Histopathology 3 (1979) 349-365
2. Metcalfe D.D. Classification and diagnosis of mastocytosis: current status. J Invest Dermatol 96 (1991) 2S-4S
3. Valent P. Biology, classification and treatment of human mastocytosis. Wien Klin Wochenschr 108 (1996) 385-397
4. Valent P., Akin C., Sperr W.R., et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol 122 (2003) 695-717
5. Akin C., and Metcalfe D.D. Systemic mastocytosis. Annu Rev Med 55 (2004) 419-432
6. Valent P., Horny H.-P., Escribano L., et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Conference Report of "Year 2000 Working Conference on Mastocytosis.". Leuk Res 25 (2001) 603-625
7. Valent P., Akin C., Escribano L., et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 37 (2007) 435-453
8. Wilson TM, Metcalfe DD, Robyn J. Treatment of systemic mastocytosis. In: Immunol Allergy Clin North Am. 2006;26:549-573.
9. Valent P., Ghannadan M., Akin C., et al. On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts. Eur J Clin Invest 34 (2004) 41-52
10. Macy D.W. Canine mast cell tumors. Vet Clin North Am Small Anim Pract 15 (1985) 783-803
11. London C.A., and Seguin B. Mast cell tumors in the dog. Vet Clin North Am Small Anim Pract 33 (2003) 473-489
12. Misdorp W. Mast cells and canine mast cell tumours. A review. Vet Q 26 (2004) 156-169
13. Rogers K.S. Mast cell tumors: dilemmas of diagnosis and treatment. Vet Clin North Am Small Anim Pract 26 (1996) 87-102
14. Govier S.M. Principles of treatment for mast cell tumors. Clin Tech Small Anim Pract 18 (2003) 103-106
15. Cahalane A.K., Payne S., Barber L.G., et al. Prognostic factors for survival of dogs with inguinal and perineal mast cell tumors treated surgically with or without adjunctive treatment: 68 cases (1994-2002). J Am Vet Med Assoc 225 (2004) 401-408
16. Nagata H., Worobec A.S., Oh C.K., et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A 92 (1995) 10560-10564
17. Longley B.J., Tyrrell L., Lu S.Z., et al. Somatic c-kit activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 12 (1996) 312-314
18. Fritsche-Polanz R., Jordan J.H., Feix A., et al. Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol 113 (2001) 357-364
19. London C.A., Galli S.J., Yuuki T., et al. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp Hematol 27 (1999) 689-697
20. Zemke D., Yamini B., and Yuzbasiyan-Gurkan V. Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs. Vet Pathol 39 (2002) 529-535
21. Jones C.L., Grahn R.A., Chien M.B., et al. Detection of c-kit mutations in canine mast cell tumors using fluorescent polyacrylamide gel electrophoresis. J Vet Diagn Invest 16 (2004) 95-100
22. Riva F., Brizzola S., Stefanello D., et al. A study of mutations in the c-kit gene of 32 dogs with mastocytoma. J Vet Diagn Invest 17 (2005) 385-388
23. Webster J.D., Yuzbasiyan-Gurkan V., Miller R.A., Kaneene J.B., and Kiupel M. Cellular proliferation in canine cutaneous mast cell tumors: associations with c-KIT and its role in prognostication. Vet Pathol 44 (2007) 298-308
24. Webster J.D., Kiupel M., and Yuzbasiyan-Gurkan V. Evaluation of the kinase domain of c-KIT in canine cutaneous mast cell tumors. BMC Cancer 6 (2006) 85
25. Taylor M.L., and Metcalfe D.D. Kit signal transduction. Hematol Oncol Clin North Am 14 (2000) 517-535
26. Casteran N., De Sepulveda P., Beslu N., et al. Signal transduction by several KIT juxtamembrane domain mutations. Oncogene 22 (2003) 4710-4722
27. Shivakrupa R., Bernstein A., Watring N., and Linnekin D. Phosphatidylinositol 3'-kinase is required for growth of mast cells expressing the kit catalytic domain mutant. Cancer Res 63 (2003) 4412-4419
28. Dennery P.A. Regulation and role of heme oxygenase in oxidative injury. Curr Top Cell Regul 36 (2000) 181-199
29. Morse D., and Choi A.M. Heme oxygenase-1: the "emerging molecule" has arrived. Am J Respir Cell Mol Biol 27 (2002) 8-16
30. Takahashi T., Morita K., Akagi R., and Sassa S. Heme oxygenase-1: a novel therapeutic target in oxidative tissue injuries. Curr Med Chem 11 (2004) 1545-1561
31. Doi K., Akaike T., Fujii S., et al. Induction of haem oxygenase-1 nitric oxide and ischaemia in experimental solid tumours and implications for tumour growth. Br J Cancer 80 (1999) 1945-1954
32. Fang J., Sawa T., Akaike T., et al. In vivo antitumor activity of pegylated zinc protoporphyrin: targeted inhibition of heme oxygenase in solid tumor. Cancer Res 63 (2003) 3567-3574
33. Fang J., Sawa T., Akaike T., Greish K., and Maeda H. Enhancement of chemotherapeutic response of tumor cells by a heme oxygenase inhibitor, pegylated zinc protoporphyrin. Int J Cancer 109 (2004) 1-8
34. Mayerhofer M., Gleixner K.V., Mayerhofer J., et al. Targeting of heat shock protein 32 (Hsp32) / heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib. Blood 111 (2008) 2200-2210
35. Liu Z.M., Chen G.G., Ng E.K., Leung W.K., Sung J.J., and Chung S.C. Upregulation of heme oxygenase-1 and p21 confers resistance to apoptosis in human gastric cancer cells. Oncogene 23 (2004) 503-513
36. Berberat P.O., Dambrauskas Z., Gulbinas A., et al. Inhibition of heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment. Clin Cancer Res 11 (2005) 3790-3798
37. Zhou P., Kalakonda N., and Comenzo R.L. Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo. Br J Haematol 128 (2005) 636-644
38. Takamiya R., Murakami M., Kajimura M., et al. Stabilization of mast cells by heme oxygenase-1: an anti-inflammatory role. Am J Physiol Heart Circ Physiol 283 (2002) 861-870
39. Kondo R., Gleixner K.V., Mayerhofer M., et al. Identification of heat shock protein 32 (Hsp32) as a novel survival factor and therapeutic target in neoplastic mast cells. Blood 110 (2007) 661-669
40. Fabbro D., Ruetz S., Bodis S., et al. PKC412-a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 15 (2000) 17-28
41. Iyer A.K., Greish K., Fang J., Murakami R., and Maeda H. High-loading nanosized micelles of copoly(styrene-maleic acid)-zinc protoporphyrin for targeted delivery of a potent heme oxygenase inhibitor. Biomaterials 28 (2007) 1871-1881
42. Greish K., Nagamitsu A., Fang J., and Maeda H. Copoly(styrene-maleic acid)-pirarubicin micelles: high tumor-targeting efficiency with little toxicity. Bioconjug Chem 16 (2005) 230-236
43. DeVinney R., and Gold W.M. Establishment of two dog mastocytoma cell lines in continuous culture. Am J Respir Cell Mol Biol 3 (1990) 413-420
44. Rebuzzi L., Willmann M., Sonneck K., et al. Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells. Vet Immunol Immunopathol 115 (2007) 320-333
45. Valent P., Ashman L.K., Hinterberger W., et al. Mast cell typing: demonstration of a distinct hematopoietic cell type and evidence for immunophenotypic relationship to mononuclear phagocytes. Blood 73 (1989) 1778-1785
46. Gleixner K., Mayerhofer M., Aichberger K., et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA), and evaluation of cooperative drug effects. Blood 107 (2005) 752-759
47. Agis H., Krauth M.T., Mosberger I., et al. Enumeration and immunohistochemical characterisation of bone marrow basophils in myeloproliferative disorders using the basophil specific monoclonal antibody 2D7. J Clin Pathol 59 (2006) 396-402
48. Gleixner K.V., Rebuzzi L., Mayerhofer M., et al. Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells. Exp Hematol 35 (2007) 1510-1521